{
    "clinical_study": {
        "@rank": "164719", 
        "arm_group": {
            "arm_group_label": "LDK378 and AUY922", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The primary purpose of the study is to estimate the maximum tolerated dose of the\n      combination of LDK378 and AUY922.  This study will assess the safety, tolerability,\n      pharmacokinetics and preliminary evidence of anti-tumor activity of the combination of\n      LDK378 and AUY922 in ALK-rearranged non-small cell lung cancer."
        }, 
        "brief_title": "Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Anaplastic Lymphoma Kinase (ALK)", 
            "Non-small Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  locally advanced or metastatic NSCLC that has progressed during or following therapy\n             with an ALK inhibitor\n\n          -  tumor must carry an ALK rearrangement in 15% or more of tumor cells as measured by\n             FISH\n\n          -  disease that can be evaluated by RECIST v1.1 and measurable disease\n\n        Exclusion Criteria:\n\n          -  central nervous system (CNS) metastases that are symptomatic or require increasing\n             steroids or CNS-directed therapy to control CNS disease\n\n          -  history of interstitial lung disease or interstitial pneumonitis, including\n             clinically significant radiation pneumonitis\n\n          -  clinically significant cardiac dysfunction\n\n          -  inadequate end organ function as defined by specified laboratory values\n\n          -  use of medications known to be strong inhibitors or inducters of CYP3A4/5 that cannot\n             be discontinued at least 1 week prior to start of treatment\n\n          -  use of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be\n             discontinued at least 1 week prior to start of treatment\n\n          -  clinically significant, uncontrolled impaired gastrointestinal function or GI disease\n\n          -  prior treatment with a HSP90 inhibitor\n\n          -  radiotherapy to lung within 4 weeks prior to the first dose of study treatment or\n             patients who have not recovered from radiotherapy-related toxicities\n\n          -  pregnant or nursing women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "142", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772797", 
            "org_study_id": "CLDK378X2102", 
            "secondary_id": "2012-004632-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "LDK378 and AUY922", 
                "description": "LDK378 is a capsule to be taken daily by mouth.", 
                "intervention_name": "LDK378", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LDK378 and AUY922", 
                "description": "AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.", 
                "intervention_name": "AUY922", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "anaplastic lymphoma kinase, ALK-rearranged lung cancer, non-small cell lung cancer", 
        "lastchanged_date": "March 6, 2014", 
        "location": [
            {
                "contact": {
                    "email": "tglass@seattlecca.org", 
                    "last_name": "Roberta Kay Silveira", 
                    "phone": "+1 720 848 0655"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Dept. of Anschutz Cancer (3)"
                }, 
                "investigator": {
                    "last_name": "Ross Camidge", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "617-724-1223"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Massachusetts General Hospital Mass General"
                }, 
                "investigator": {
                    "last_name": "Alice Shaw", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Stephanie.Rosati@fccc.edu", 
                    "last_name": "Stephanie Rosati", 
                    "phone": "215-214-4297"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111-2497"
                    }, 
                    "name": "Fox Chase Cancer Center Fox Chase Cancer (2)"
                }, 
                "investigator": {
                    "last_name": "Ranee Mehra", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jessica.moehle@hci.utah.edu", 
                    "last_name": "Jeff Pettey", 
                    "phone": "801-585-0443"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "University of Utah / Huntsman Cancer Institute Huntsman"
                }, 
                "investigator": {
                    "last_name": "Sunil Sharma", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20141"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "169610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Cataluna", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Italy", 
                "Singapore", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "cycle = within the first 28 days of patient's first dose", 
            "measure": "Incidence rate of Dose Limiting Toxicities (DLT)", 
            "safety_issue": "Yes", 
            "time_frame": "up to day 28 after the patient's first dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772797"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Characterize the safety and tolerability of LDK378 and AUY922 in patients", 
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LDK378 and AUY922 in patients", 
                "measure": "Changes in laboratory values", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LDK378 and AUY922 in patients", 
                "measure": "Assessments of electrocardiograms", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LDK378 and AUY922 in patients", 
                "measure": "Assessments of dose interruptions, reductions, and dose intensity", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple dose PK of LDK378 and AUY922 in patients", 
                "measure": "Plasma PK parameter of LDK378 and AUY922: Tmax", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LDK378 and AUY922", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LDK378 and AUY922", 
                "measure": "Duration of Response (DoR)", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LDK378 and AUY922", 
                "measure": "Time to Response (TTR)", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LDK378 and AUY922 per RECIST 1.1", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LDK378 and AUY922 in patients", 
                "measure": "Number of patients with serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple dose PK of LDK378 and AUY922 in patients", 
                "measure": "Plasma PK parameter of LDK378 and AUY922: Cmax", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple dose PK of LDK378 and AUY922 in patients", 
                "measure": "Plasma PK parameter of LDK378 and AUY922: AUClast", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple dose PK of LDK378 and AUY922 in patients", 
                "measure": "Plasma PK parameter of LDK378 and AUY922: AUCtau", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple dose PK of LDK378 and AUY922 in patients", 
                "measure": "Plasma PK parameter of LDK378 and AUY922: Cmin", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple dose PK of LDK378 and AUY922 in patients", 
                "measure": "Plasma PK parameter of LDK378 and AUY922: Racc", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}